Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
Approval based on phase III data showing unprecedented functional cure rates compared to standard of care ...
In September 2026, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation approved ...
The Kansas City Chiefs avoided a historic Super Bowl era stat on Sunday, snapping a three-game stretch without a sack during ...
Washington State University researchers have engineered a targeted nanotherapy that could yield a medical breakthrough to ...
On the eve of New Scientist’s 70th anniversary, newsroom legend Andy Coghlan reveals four of the most dramatic and surprising ...
Soon if you visit a medical specialist, you may notice a fact sheet plastered on the wall. It will encourage you to ask questions, and outline five simple things to consider when speaking to your ...
Becton, Dickinson and Company (NYSE:BDX) has steady demand for its medical devices, together with a long history of paying ...
Abbott Laboratories (NYSE:ABT) is one of the top 10 picks in President Trump’s latest stock portfolio. Trump bought $1 ...
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials ...
The gains of scientific advancements in treatment are shadowed by the cuts coming in Medicaid coverage at rare disease fair.
The first half of December marked a decisive conclusion to the year for Saudi Arabia, characterized by the approval of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results